According to the Zhitong Finance App, Fuan Pharmaceutical (300194.SZ) released its 2023 annual report. During the reporting period, the company achieved revenue of 2,648 billion yuan, an increase of 9.33% over the previous year. Achieved net profit attributable to shareholders of listed companies of 232 million yuan, an increase of 13.32% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 16.4883 million yuan, a year-on-year decrease of 89.94%. Basic earnings per share were $0.19. It is proposed to distribute a cash dividend of 0.5 yuan (tax included) for every 10 shares to all shareholders.